Download full-text PDF

Source
http://dx.doi.org/10.1053/j.jvca.2017.12.014DOI Listing

Publication Analysis

Top Keywords

inhaled nitric
4
nitric oxide
4
oxide ino
4
ino inhaled
4
inhaled epoprostenol
4
epoprostenol ipgi
4
ipgi cardiothoracic
4
cardiothoracic surgical
4
surgical patients
4
patients sufficient
4

Similar Publications

Background: Plasma exchange (PE) removes high-molecular-weight substances and is sometimes used for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) with alveolar hemorrhage. Hypotension during PE is rare, except in allergic cases. We report a case of shock likely caused by increased pulmonary vascular resistance (PVR) during PE.

View Article and Find Full Text PDF

Advances in Electrochemical Nitrite Reduction toward Nitric Oxide Synthesis for Biomedical Applications.

Adv Healthc Mater

January 2025

Center for High Altitude Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.

Nitric oxide (NO) is an essential molecule in biomedicine, recognized for its antibacterial properties, neuronal modulation, and use in inhalation therapies. The effectiveness of NO-based treatments relies on precise control of NO concentrations tailored to specific therapeutic needs. Electrochemical generation of NO (E-NOgen) via nitrite (NO ) reduction offers a scalable and efficient route for controlled NO production, while also addressing environmental concerns by reducing NO pollution and maintaining nitrogen cycle balance.

View Article and Find Full Text PDF

Objectives: Many chemicals have been used for industrial purposes, and some of them are carcinogenic to humans. However, their molecular mechanisms have not been well understood. Reactive oxygen species are generated from industrial chemicals and contribute to carcinogenesis.

View Article and Find Full Text PDF

The term "asthma-chronic obstructive pulmonary disease (COPD) combined phenotype" describes patients with persistent airflow limitation and features of both asthma and COPD. There is a lack of data on effective treatments for this group, often excluded from asthma or COPD trials. Inhaled corticosteroids (ICS) are standard for asthma, while bronchodilators are key for COPD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!